Key result
Intramuscular injection of a myosin transgene restored intrinsic force-generating capacity and normalized myofiber size in a mouse model of ACTA1-related nemaline myopathy.
Why the study?
Does in vivo intramuscular injection of a myosin transgene restore muscle function and morphology in a mouse model of nemaline myopathy?
Does in vivo intramuscular injection of a myosin transgene restore muscle function and morphology in a mouse model of nemaline myopathy?
Gene therapy delivering a myosin transgene restores muscle force and normalizes fiber size in a mouse model of ACTA1-related nemaline myopathy, suggesting a novel therapeutic target.
May advance gene therapy for ACTA1 nemaline myopathy; leaves open translation to human trials.
OBJECTIVE: Nemaline myopathy, one of the most common congenital myopathies, is associated with mutations in various genes including ACTA1. This disease is also characterized by various forms/degrees of muscle weakness, with most cases being severe and resulting in death in infancy. Recent findings have provided valuable insight into the underlying pathophysiological mechanisms. Mutations in ACTA1 directly disrupt binding interactions between actin and myosin, and consequently the intrinsic force-generating capacity of muscle fibers. ACTA1 mutations are also associated with variations in myofiber size, the mechanisms of which have been unclear. In the present study, we sought to test the hypotheses that the compromised functional and morphological attributes of skeletal muscles bearing ACTA1 mutations (1) would be directly due to the inefficient actomyosin complex and (2) could be restored by manipulating myosin expression. METHODS: We used a knockin mouse model expressing the ACTA1 His40Tyr actin mutation found in human patients. We then performed in vivo intramuscular injections of recombinant adeno-associated viral vectors harboring a myosin transgene known to facilitate muscle contraction. RESULTS: We observed that in the presence of the transgene, the intrinsic force-generating capacity was restored and myofiber size was normal. INTERPRETATION: This demonstrates a direct link between disrupted attachment of myosin molecules to actin monomers and muscle fiber atrophy. These data also suggest that further therapeutic interventions should primarily target myosin dysfunction to alleviate the pathology of ACTA1-related nemaline myopathy. Ann Neurol 2016;79:717-725.
No takes yet. Share an insight, caveat, or question.
Lindqvist et al. (2016) studied Nemaline myopathy. Intramuscular injections of recombinant adeno-associated viral vectors harboring a myosin transgene was evaluated on Intrinsic force-generating capacity and myofiber size. Intramuscular injection of a myosin transgene restored intrinsic force-generating capacity and normalized myofiber size in a mouse model of ACTA1-related nemaline myopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: